N
Nuvectis
Biotech & Life Sciences · Fort Lee, United States · IPO 2022
Innovative biopharmaceuticals targeting cancer with novel oral small molecule inhibitors MoreLess
Nuvectis Pharma, Inc. is a biopharmaceutical company specializing in the development of targeted therapies for cancer treatment. The company focuses on creating novel oral small molecule inhibitors, specifically NXP800 and NXP900, which target the HSF1 pathway and SRC YES1 kinase, respectively. Nuvectis serves patients with ovarian clear cell carcinoma (OCCC) and advanced stage endometrioid ovarian cancer. Founded in 2020, the company operates in the oncology market and leverages its expertise in target selection, drug profiling, and clinical and regulatory execution to build its pipeline. Nuvectis generates revenue through the development and potential commercialization of its drug candidates. The company is led by a team of industry veterans with extensive experience in drug development and regulatory success.
Keywords: biopharmaceutical, cancer, targeted therapies, oral inhibitors, HSF1 pathway, SRC YES1 kinase, oncology, ovarian cancer, drug development, clinical trials.
Company overview
Nuvectis company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- —
- Headquarters
- Fort Lee, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 0.0
Valuation & funding
Nuvectis funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Jul 2026 | $115M | — | Tang Capital · Sphera Funds Management · Polus Capital · Soleus Capital | ↗ |
| POST IPO EQUITY✓Other financing | May 2025 | $60M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Feb 2025 | $14M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jul 2022 | $16M | — | Undisclosed | ↗ |
| IPO✓Exit | Feb 2022 | $0 | — | Undisclosed | — |
| LATE VCEquity / VC | Oct 2021 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin | Profit | Margin | R&D |
|---|---|---|---|---|---|---|---|
| 2026 | $0 | — | −$28M | — | −$26M | — | $18M |
| 2025 | $0 | — | −$28M | — | −$26M | — | $18M |
| 2024 | $0 | — | −$20M | — | −$19M | — | $13M |
| 2023 | $0 | — | −$23M | — | $15M | ||
| 2022 | $0 | — | −$19M | — | |||
| 2021 | — | — | −$13M | — |
Growth signals
Nuvectis website traffic
Latest recorded traffic for Nuvectis is 5.2K monthly website visits, up 881.1% over the last three months.
Comparisons
Nuvectis compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Nuvectis's talent
Source: Dealroom Talent Intelligence.
Investors
7 investors on Nuvectis's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Nuvectis has talent and traffic
team presence
In the news
Latest news about Nuvectis
Recent press, funding announcements, and product moves mentioning Nuvectis — open to read from the original sources.
Market sentiment
What the market is saying about Nuvectis
An AI-synthesized read of the highest-engagement posts about Nuvectis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nuvectis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.